Thus, the combination of HSP90 inhibitors with CIK cells has demonstrated the ability to enhance late apoptosis in Burkitt’s lymphoma (BL), particularly with ganetespib. This evidence concerns the gene HSP90AA1 and Burkitt lymphoma.